B-intervention	0	4	Dose
I-intervention	4	5	-
I-intervention	5	10	dense
I-intervention	11	19	adjuvant
I-intervention	20	32	chemotherapy
O	33	36	for
B-eligibility	37	41	node
I-eligibility	41	42	-
I-eligibility	42	50	positive
I-eligibility	51	57	breast
I-eligibility	58	64	cancer
I-eligibility	65	67	in
I-eligibility	68	73	women
I-eligibility	74	76	60
I-eligibility	77	82	years
I-eligibility	83	86	and
I-eligibility	87	92	older
O	92	93	:
O	94	105	feasibility
O	106	109	and
O	110	122	tolerability
O	123	125	in
O	126	127	a
O	128	134	subset
O	135	137	of
O	138	146	patients
O	147	149	in
O	150	151	a
O	152	162	randomized
O	163	168	trial
O	168	169	.

O	170	172	To
O	173	181	evaluate
O	182	185	the
O	186	197	feasibility
O	198	201	and
O	202	214	tolerability
O	215	217	of
O	218	222	dose
O	222	223	-
O	223	228	dense
O	229	237	adjuvant
O	238	250	chemotherapy
O	251	254	for
B-eligibility	255	260	older
I-eligibility	261	269	patients
I-eligibility	270	274	with
I-eligibility	275	279	node
I-eligibility	279	280	-
I-eligibility	280	288	positive
I-eligibility	289	295	breast
I-eligibility	296	302	cancer
O	302	303	,
O	304	305	a
O	306	319	retrospective
O	320	326	subset
O	327	335	analysis
O	336	344	compared
O	345	349	dose
O	350	356	delays
O	357	360	and
O	361	365	dose
O	366	376	reductions
O	377	380	for
O	381	386	women
O	387	391	aged
B-age	392	393	>
I-age	394	396	or
I-age	397	398	=
I-age	399	401	60
I-age	402	407	years
O	408	412	with
O	413	418	those
O	419	421	of
O	422	429	younger
O	430	435	women
O	435	436	.

O	437	445	Patients
O	446	450	were
O	451	461	randomized
O	462	464	to
O	465	466	a
O	467	471	dose
O	471	472	-
O	472	477	dense
O	478	479	(
O	479	481	DD
O	481	482	,
O	483	485	14
O	485	486	-
O	486	489	day
O	490	495	cycle
O	495	496	)
O	497	499	or
B-control	500	512	conventional
I-control	512	513	-
I-control	513	521	schedule
O	522	523	(
O	523	525	CS
O	525	526	,
O	527	529	21
O	529	530	-
O	530	533	day
O	534	539	cycle
O	539	540	)
O	541	548	regimen
O	548	549	.

O	550	552	DD
O	553	561	patients
O	562	563	(
O	563	564	n
O	565	566	=
B-intervention-participants	567	570	104
O	570	571	;
O	572	574	25
O	575	579	aged
O	580	581	>
O	582	584	or
O	585	586	=
O	587	589	60
O	590	595	years
O	595	596	)
O	597	605	received
O	606	616	epirubicin
O	617	619	90
O	620	622	mg
O	622	623	/
O	623	625	m2
O	626	630	plus
O	631	641	paclitaxel
O	642	645	175
O	646	648	mg
O	648	649	/
O	649	651	m2
O	652	653	(
O	653	657	four
O	658	664	cycles
O	664	665	)
O	665	666	,
O	667	671	then
O	672	688	cyclophosphamide
O	689	692	600
O	693	695	mg
O	695	696	/
O	696	698	m2
O	698	699	,
O	700	712	methotrexate
O	713	715	40
O	716	718	mg
O	718	719	/
O	719	721	m2
O	722	725	and
O	726	738	fluorouracil
O	739	742	600
O	743	745	mg
O	745	746	/
O	746	748	m2
O	749	750	(
O	750	753	CMF
O	754	757	600
O	757	758	/
O	758	760	40
O	760	761	/
O	761	764	600
O	764	765	)
O	766	767	(
O	767	772	three
O	773	779	cycles
O	779	780	)
O	780	781	,
O	782	786	plus
O	787	797	filgrastim
O	798	799	5
O	800	806	microg
O	806	807	/
O	807	809	kg
O	810	813	per
O	814	817	day
O	818	820	in
O	821	826	every
O	827	832	cycle
O	832	833	.

O	834	836	CS
O	837	845	patients
O	846	847	(
O	847	848	n
O	849	850	=
B-control-participants	851	854	107
O	854	855	;
O	856	858	27
O	859	863	aged
O	864	865	>
O	866	868	or
O	869	870	=
O	871	873	60
O	874	879	years
O	879	880	)
O	881	889	received
O	890	900	epirubicin
O	901	903	90
O	904	906	mg
O	906	907	/
O	907	909	m2
O	910	914	plus
O	915	931	cyclophosphamide
O	932	935	600
O	936	938	mg
O	938	939	/
O	939	941	m2
O	942	943	(
O	943	947	four
O	948	954	cycles
O	954	955	)
O	955	956	,
O	957	961	then
O	962	965	CMF
O	966	969	600
O	969	970	/
O	970	972	40
O	972	973	/
O	973	976	600
O	977	978	(
O	978	983	three
O	984	990	cycles
O	990	991	)
O	991	992	,
O	993	997	plus
O	998	1008	filgrastim
O	1009	1011	if
O	1012	1020	required
O	1020	1021	.

B-outcome	1022	1028	Delays
O	1029	1033	were
O	1034	1038	more
O	1039	1045	common
O	1046	1048	in
O	1049	1054	older
O	1055	1063	patients
O	1064	1066	in
O	1067	1071	both
O	1072	1075	the
O	1076	1078	DD
O	1079	1082	and
O	1083	1085	CS
O	1086	1092	groups
O	1093	1094	(
O	1094	1096	DD
O	1096	1097	,
B-iv-bin-percent	1098	1100	17
I-iv-bin-percent	1100	1101	%
O	1102	1108	versus
B-iv-bin-percent	1109	1110	6
I-iv-bin-percent	1110	1111	%
O	1111	1112	;
O	1113	1115	CS
O	1115	1116	,
B-cv-bin-percent	1117	1119	11
I-cv-bin-percent	1119	1120	%
O	1121	1127	versus
B-cv-bin-percent	1128	1129	6
I-cv-bin-percent	1129	1130	%
O	1130	1131	)
O	1131	1132	,
O	1133	1135	as
O	1136	1140	were
B-outcome	1141	1147	Grades
I-outcome	1148	1149	3
I-outcome	1149	1150	-
I-outcome	1150	1151	4
I-outcome	1152	1162	leukopenia
O	1163	1164	(
B-iv-bin-percent	1164	1166	26
I-iv-bin-percent	1166	1167	%
O	1168	1174	versus
B-cv-bin-percent	1175	1177	12
I-cv-bin-percent	1177	1178	%
O	1178	1179	)
O	1180	1183	and
B-outcome	1184	1195	neutropenia
O	1196	1197	(
B-iv-bin-percent	1197	1199	33
I-iv-bin-percent	1199	1200	%
O	1201	1207	versus
B-cv-bin-percent	1208	1210	25
I-cv-bin-percent	1210	1211	%
O	1211	1212	)
O	1212	1213	.

O	1214	1217	All
O	1218	1223	older
O	1224	1226	DD
O	1227	1230	and
O	1231	1233	89
O	1233	1234	%
O	1235	1237	of
O	1238	1243	older
O	1244	1246	CS
O	1247	1255	patients
O	1256	1264	received
O	1265	1268	all
O	1269	1274	seven
O	1275	1287	chemotherapy
O	1288	1294	cycles
O	1294	1295	,
O	1296	1300	with
O	1301	1303	99
O	1303	1304	%
O	1305	1307	of
O	1308	1314	cycles
O	1315	1317	at
O	1318	1322	full
O	1323	1327	dose
O	1327	1328	.

O	1329	1333	This
O	1334	1339	study
O	1340	1352	demonstrates
O	1353	1357	that
O	1358	1359	a
O	1360	1364	dose
O	1364	1365	-
O	1365	1370	dense
O	1371	1378	regimen
O	1379	1388	combining
O	1389	1399	epirubicin
O	1400	1403	and
O	1404	1414	paclitaxel
O	1415	1418	can
O	1419	1421	be
O	1422	1434	administered
O	1435	1437	to
O	1438	1446	patients
O	1447	1448	>
O	1449	1451	or
O	1452	1453	=
O	1454	1456	60
O	1457	1462	years
O	1463	1465	of
O	1466	1469	age
O	1470	1474	with
O	1475	1476	a
O	1477	1486	tolerable
O	1487	1493	safety
O	1494	1501	profile
O	1501	1502	.
